JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Key facts
- Where
- Allentown, Boston, Cleveland, Columbia, Columbus, Detroit, Fayetteville, Galveston, Houston, Huntsville, Iowa City, Jacksonville, Kingsport, La Jolla, Lakeland, Little Rock, Louisville, Miami, New York, Newark, Norfolk, Philadelphia, Pittsburgh, Portland, San Diego, Staten Island, Tucson, and Washington D.C., United StatesSee the 29 sites
Where in United States
- Lehigh Valley Health NetworkAllentown, United StatesContact: Deborah MankosTaking people
- Tufts Medical CenterBoston, United StatesContact: Gaurav DasTaking people
- The Cleveland Clinical FoundationCleveland, United StatesContact: Larissa Schaaf, RNTaking people
- University of MissouriColumbia, United StatesContact: Jennifer RandolphTaking people
- The Ohio State UniversityColumbus, United StatesContact: Noel DeSistoNo longer taking part
- Henry Ford HospitalDetroit, United StatesContact: Noel DeSistoNo longer taking part
- Washington Regional Medical CenterFayetteville, United StatesTaking people
- The University of Texas Medical Branch at GalvestonGalveston, United StatesContact: Sana MalikTaking people
- Houston Methodist Research InstituteHouston, United StatesContact: Solange BasagoitiaTaking people
- Huntsville HospitalHuntsville, United StatesContact: Noel DeSistoNo longer taking part
- University of Iowa Hospitals and ClinicsIowa City, United StatesContact: Noel DeSistoNo longer taking part
- Jacksonville Center for Clinical ResearchJacksonville, United StatesContact: Lisa JosephTaking people
- Wellmont Cardiology ServicesKingsport, United StatesContact: Joshua LesterTaking people
- The Regents of the University of California - San DiegoLa Jolla, United StatesContact: Kathleen GrohTaking people
- Radiology and Imaging SpecialistsLakeland, United StatesContact: Eve JohnsonTaking people
- Central Arkansas Veterans Healthcare SystemLittle Rock, United StatesContact: Sandra BrockTaking people
- University of LouisvilleLouisville, United StatesContact: Leslie HaysleyTaking people
- Baptist Hospital of Miami, Miami Cardiac and Vascular InstituteMiami, United StatesContact: David FernandezTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Jack WaitzTaking people
- Newark Beth Israel Medical CenterNewark, United StatesContact: Debra CookTaking people
- Sentara HospitalsNorfolk, United StatesContact: Kara Wiggins, MSN, RNTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Thomas HebertTaking people
- Allegheny Health NetworkPittsburgh, United StatesContact: Sheila BernardiniTaking people
- Oregon Health Sciences UniversityPortland, United StatesContact: Amie LorischTaking people
- U.S. Department of Veterans Affairs, VA Portland Health Care SystemPortland, United StatesContact: Jin KimTaking people
- Veterans Affairs San Diego Healthcare SystemSan Diego, United StatesContact: Annalicia VargasTaking people
- Feinstein Institutes for Medical Research (Staten Island University Hospital/Northwell Health)Staten Island, United StatesContact: Alexandra PanteaTaking people
- University of ArizonaTucson, United StatesContact: Karen SanchezTaking people
- MedStar Washington Hospital CenterWashington D.C., United StatesContact: Kassaye SesabaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Endologix
- Trial code
- NCT05064540
- Record updated
- 9 September 2026
- Original description
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.Read full original descriptionShow less
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.
Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Inclusion: Adult age 21 and older; Subjects with minimum of 2 year life expectancy; Subjects have signed the informed consent document; Subjects with unruptured infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices; Patient must be able and willing to comply with all required follow-up exams.
Exclusion: Subjects with pre-existing EVAR, i.e., in need of repair/intervention of a previously failed EVAR; Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations; Known allergy to any of the device components; Known connective tissue disorders; Known active infection; Currently participating in another trial where the primary endpoint has not been reached yet; Pregnant (females of childbearing potential only).